TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03564860

Intervention type: PROCEDURE
Intervention: Device data collection
Description: Collection of device electrograms and 12-lead ECG during a device follow-up visit
Study: NCT00707551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Tablet, administered as repeated doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Extended Release tablet, administered as repeated doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Extended Release tablet, administered as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Extended Release tablet, administered as a single dose.
Study: NCT02632188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-PMAT treatment
Description: Postoperative routine treatment according to the hospitals local routines; DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study: NCT00707551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Extended Release tablet, administered as a single dose.
Study: NCT02828852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.~In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.~In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed.
Study: NCT00919620

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stage-specific case-management
Description: Stage-specific case-management for psychosis by designated key-workers according to specified protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stage-specific case-management
Description: Stage-specific case-management for psychosis by designated key-workers according to specified protocol
Study: NCT06342440

Intervention type: DIAGNOSTIC_TEST
Intervention: DENEB
Description: A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: DENEB
Description: A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: DENEB
Description: A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: DENEB
Description: A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: DENEB
Description: A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: DENEB
Description: A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: DENEB
Description: A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: DENEB
Description: A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.
Study: NCT00409565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: * Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY~* Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
Study: NCT03373422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Various dosing OD (once daily) and BID (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Various dosing OD (once daily) and BID (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Various dosing OD (once daily) and BID (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Various dosing OD (once daily) and BID (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Various dosing OD (once daily) and BID (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT03517150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mandibular advancement device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mandibular advancement device
Study: NCT02319265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Oral liquid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin
Description: Oral liquid
Study: NCT04192292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP4 Inhibitor
Description: Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP4 Inhibitor
Description: Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.
Study: NCT00915421

Intervention type: PROCEDURE
Intervention: Induction of therapeutic mild hypothermia
Description: Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
Study: NCT02090920

Intervention type: DRUG
Intervention: Nifedipine
Description: Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
Study: NCT02056808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMT C1100
Description: Comparison of safety and pharmacokinetic of different dosages of drug
Study: NCT03007472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI532
Description: Cochlear implant
Study: NCT01406197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Vaginal progesterone
Description: Vaginal progesterone formulation (150 mg micronized progesterone daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Topical progesterone
Description: Progesterone will be applied daily (150 mg micronized progesterone)by topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Intramuscular progesterone
Description: Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).
Study: NCT03007472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus 7
Description: Sound processor
Study: NCT00269867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
Study: NCT02594150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
Study: NCT00287261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg IV every 3 weeks for 36 weeks
Study: NCT03922945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521 oral capsule
Description: Phentermine/Topiramate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521 oral capsule
Description: Phentermine/Topiramate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Inactive drug

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Modification
Description: The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
Study: NCT03532464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
Study: NCT03922945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
Study: NCT00714831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: 3-months physical activity intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health educational program
Description: Health education sessions and stretching sessions
Study: NCT03065010

Intervention type: DRUG
Group type: OTHER
Intervention: BCD-115
Description: Inhibitor of CDK8/19
Study: NCT03088306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard analgesia use [Oxygen]
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard analgesia use [Hydromorphone]
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard analgesia use [Volatile Anesthesia]
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard analgesia use [Fentanyl]
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal pain management [Acetaminophen + Gabapentin]
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal pain management [Fentanyl]
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal pain management [Intravenous Ketamine]
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Study: NCT03532464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline
Description: The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
Study: NCT03088306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal pain management [Valium + Gabapentin]
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Study: NCT04035707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: using rocuronium as a relaxants during general anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general volatile anaesthesia
Description: method of anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general volatile anaesthesia
Description: method of anaesthesia
Study: NCT01992926

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interactive educational intervention
Description: Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
Study: NCT03076632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromyographic (EMG)-triggered (closed-loop) stimulation
Description: Force and EMG activity of specific hand muscles will be used to trigger peripheral nerve electrical stimulation or transcranial magnetic stimulation.
Study: NCT01364506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water aerobic exercise
Description: The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).~The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11.
Study: NCT04183868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: 10 mg tablet daily
Study: NCT00681421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study: NCT04183868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 2 mg
Description: starting dose: 2 mg tablet daily, 1 mg for lunch and 1 mg for dinner, can undergo to up-titration of glimepiride to a maximum of 6 mg daily
Study: NCT01857570

Intervention type: RADIATION
Intervention: Volume Computed Tomography of the wrist and carpus
Study: NCT00300976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle consultation: weight control, diet, exercise
Description: Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.~Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c \< 6.2%, BP \< 120/75 mmHg, HDL-C 40 mg/dL , LDL-C \< 80 mg/dL, TG \< 120 mg/dL.~Follow-up study (Not provided)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle consultation: weight control, diet, exercise
Description: Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.~Follow-up study (Not provided)
Study: NCT00371748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté-SR
Description: Paclitaxel-Eluting Coronary Stent, 2.25 mm

Intervention type: DEVICE
Group type: OTHER
Intervention: TAXUS™ Express2
Description: Paclitaxel-Eluting Coronary Stent System

Intervention type: DEVICE
Group type: OTHER
Intervention: Express2
Description: Coronary Stent System
Study: NCT03517410

Intervention type: OTHER
Intervention: Smart phone use
Description: Patients will be asked to use the smart phone while seated for either: (1) 10 minutes or (2) 30 minutes.
Study: NCT00749450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT00365924

Intervention type: DRUG
Group type: OTHER
Intervention: Forteo
Description: Open label single arm study with Forteo as an intervention
Study: NCT05293184

Intervention type: OTHER
Intervention: Observational study only
Study: NCT02434562

Intervention type: OTHER
Intervention: Serum (with or without urine) samples
Study: NCT02258893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO2 Scrubber
Description: an NO2 scrubber that removes NO2 and particles
Study: NCT02434562

Intervention type: OTHER
Intervention: Serum (with or without urine) samples

Intervention type: OTHER
Intervention: Serum (with or without urine) samples

Intervention type: OTHER
Intervention: Serum (with or without urine) samples
Study: NCT02524002

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Accel Gel
Description: Accel Gel by PacificHealth Labs in Matawan, NJ.
Study: NCT02280980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oculomotor and Gaze Stability Exercises
Description: Daily oculomotor and gaze stability exercises, twice a day, for three weeks
Study: NCT02524002

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Usual clear diet
Description: Usual clear liquids
Study: NCT04063592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Residual limb revision
Description: Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)
Study: NCT01736371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Sevoflurane
Description: In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: In this group the maintenance of anesthesia is maintained by only propofol infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
Study: NCT03785964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat oral tablet
Description: Nirogacestat tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat oral tablet
Description: Nirogacestat tablet
Study: NCT03015051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen